[1]丁 华.康复新液预防抗结核药品消化道不良反应的效果[J].医学信息,2023,36(17):157-160.[doi:10.3969/j.issn.1006-1959.2023.17.033]
　DING Hua.Effect of Kangfuxin Liquid on Prevention of Gastrointestinal Adverse Reactions of Anti-tuberculosis Drugs[J].Journal of Medical Information,2023,36(17):157-160.[doi:10.3969/j.issn.1006-1959.2023.17.033]
点击复制

康复新液预防抗结核药品消化道不良反应的效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年17期
页码:
157-160
栏目:
药物与临床
出版日期:
2023-09-01

文章信息/Info

Title:
Effect of Kangfuxin Liquid on Prevention of Gastrointestinal Adverse Reactions of Anti-tuberculosis Drugs
文章编号:
1006-1959（2023）17-0157-04
作者:
丁 华
（抚州市临川区疾病预防控制中心慢病科，江西 抚州 344100）
Author(s):
DING Hua
(Department of Chronic Diseases,Linchuan District Center for Disease Control and Prevention,Fuzhou 344100,Jiangxi,China)
关键词:
抗结核治疗; 康复新液; 消化道不良反应; 炎症反应; 生存质量
Keywords:
Anti-tuberculosis treatment; Kangfuxin liquid; Adverse reaction of digestive tract; Inflammatory reaction; Quality of life
分类号:
R52
DOI:
10.3969/j.issn.1006-1959.2023.17.033
文献标志码:
A
摘要:
目的 探究康复新液对抗结核药品引起消化道不良反应的预防作用。方法 选取2021年1月-2022年6月抚州市临川区疾病预防控制中心收治的80例结核病患者，按照随机数字表法分为对照组（40例）和观察组（40例）。对照组给予常规抗结核药品治疗，观察组在其基础上加用康复新液治疗。比较两组消化道不良反应发生情况（恶心、呕吐、食欲不振、腹泻等）、胃肠道症状分级量表（GSRS）评分、化疗消化道症状量表（C-GITSI）评分、血清炎症因子[肿瘤坏死因子（TNF-α）、白介素（IL-1）、C-反应蛋白（CRP）]、世界卫生组织生存质量测定表简表（WHOQOL-BREF）评分。结果 观察组消化道不良反应发生率小于对照组（P＜0.05）；两组治疗后GSRS、C-GITSI评分均高于治疗前，但观察组GSRS、C-GITSI评分低于对照组（P＜0.05）；两组治疗后TNF-α、IL-1、CRP水平低于治疗前，且观察组TNF-α、IL-1、CRP水平低于对照组（P＜0.05）；两组治疗后WHOQOL-BREF评分高于治疗前，且观察组WHOQOL-BREF评分高于对照组（P＜0.05）。结论 康复新液可减少抗结核药品引起的消化道不良反应，同时缓解其症状严重程度，可抑制机体炎症反应，有助于患者生存质量的提升。
Abstract:
Objective To explore the preventive effect of Kangfuxin Liquid on gastrointestinal adverse reactions caused by anti-tuberculosis drugs.Methods A total of 80 patients with tuberculosis admitted to Linchuan District Center for Disease Control and Prevention of Fuzhou City from January 2021 to June 2022 were selected and divided into control group (40 patients) and observation group (40 patients) according to random number table method. The control group was treated with conventional anti-tuberculosis drugs, and the observation group was treated with Kangfuxin liquid on the basis of the control group. The incidence of gastrointestinal adverse reactions (nausea, vomiting, loss of appetite, diarrhea, etc.), Gastrointestinal Symptom Rating Scale (GSRS) score, Chemotherapy Gastrointestinal Symptom Scale (C-GITSI) score, serum inflammatory factors [tumor necrosis factor (TNF-α), interleukin (IL-1), C-reactive protein (CRP)], World Health Organization Quality of Life-BREF (WHOQOL-BREF) score were compared between the two groups.Results The incidence of gastrointestinal adverse reactions in the observation group was lower than that in the control group (P<0.05). After treatment, the GSRS and C-GITSI scores of the two groups were higher than those before treatment, but the GSRS and C-GITSI scores of the observation group were lower than those of the control group (P<0.05). After treatment, the levels of TNF-α, IL-1 and CRP in the two groups were lower than those before treatment, and the levels of TNF-α, IL-1 and CRP in the observation group were lower than those in the control group (P<0.05). The WHOQOL-BREF score of the two groups after treatment was higher than that before treatment, and the WHOQOL-BREF score of the observation group was higher than that of the control group (P<0.05).Conclusion Kangfuxin liquid can reduce the gastrointestinal adverse reactions caused by anti-tuberculosis drugs, alleviate the severity of symptoms, inhibit the body’s inflammatory response, and help improve the quality of life of patients.

参考文献/References:

[1]Fiebig L,Kohl TA,Popovici O,et al.A joint cross-border investigation of a cluster of multidrug-resistant tuberculosis in Austria, Romania and Germany in 2014 using classic, genotyping and whole genome sequencing methods: lessons learnt[J].Euro Surveill,2017,22(2):30439.[2]王飞,陈彬,周琳,等.耐多药肺结核患者抗结核药物所致不良反应发生情况[J].中华传染病杂志,2017,35(2):83-87.[3]张敏,陈庆,魏书青,等.康复新液辅助抗结核化疗方案治疗肠结核的临床研究[J].中国医院用药评价与分析,2022,22(1):29-31,37.[4]康冠楠,党萍,马清艳,等.芪参益肺汤联合康复新液治疗老年肺结核疗效及对患者肺功能、免疫功能的影响[J].陕西中医,2021,42(10):1393-1396.[5]康冠楠,侯莉莉,马清艳,等.康复新液联合二线药物对老年耐多药结核病患者影响的临床研究[J].新疆医科大学学报,2020,43(6):754-757,762.[6]Jaleta KN,Gizachew M,Gelaw B,et al.Rifampicin-resistant Mycobacterium tuberculosis among tuberculosis-presumptive cases at University of Gondar Hospital, northwest Ethiopia[J].Infect Drug Resist,2017,10:185-192.[7]Girum T,Tariku Y,Dessu S.Survival Status and Treatment Outcome of Multidrug Resistant Tuberculosis (MDR-TB) among Patients Treated in Treatment Initiation Centers (TIC) in South Ethiopia: A Retrospective Cohort Study[J].Annals of Medical and Health Sciences Research,2017,7(5):331-336.[8]李卉,张宏亮,杨天燕,等.我院125例抗结核药物不良反应报告分析[J].中国医药导报,2020,17(29):151-154.[9]苏圆圆,王月彩,臧卫波,等.抗结核药物不良反应的观察及预防措施[J].医学动物防制,2021,37(2):143-145.[10]李慧,田芝奥,吴霞.648例结核病患者抗结核药物所致不良反应及危险因素分析[J].中国防痨杂志,2017,39(11):1241-1246.[11]高利臣,曹仕鹏,鲁虹,等.121例二线抗结核药品不良反应分析[J].中国感染控制杂志,2018,17(12):1070-1074.[12]张敏,高金昙,马静,等.康复新液对溃疡型肠结核患者疗效及血清EGF、IL-1、TNF-α水平的影响[J].解放军医药杂志,2018,30(11):74-77.[13]高华,石海萍,张权武,等.康复新液辅助纤维支气管镜灌注联合化疗对耐多药肺结核患者肺功能、炎症因子和T淋巴细胞亚群的影响[J].现代生物医学进展,2020,20(21):4147-4151.[14]王姬,谢固雅,冯马龙.康复新液联合标准化疗方案治疗空洞型肺结核并发咯血93例[J].医药导报,2018,37(4):429-433.[15]吴世泉.康复新液联合泮托拉唑治疗溃疡性上消化道出血的临床观察[J].中华全科医学,2017,15(11):1997-1999.[16]李文博,刘超,孙扬,等.康复新液联合支气管镜下注射药物治疗复治涂阳空洞型肺结核疗效及对免疫功能和呼吸功能的影响[J].现代中西医结合杂志,2017,26(27):2972-2975,2988.[17]汪胤,唐硕润.康复新液与薄芝糖肽联合抗结核药物治疗肺结核合并糖尿病的疗效研究[J].湖南师范大学学报(医学版),2022,19(2):77-81.[18]蒋博峰,马晨晨,陈阳贵,等.抗结核药物不良反应发生率及其影响因素分析[J].中华疾病控制杂志,2017,21(2):160-163.[19]周亚飞.康复新辅助胸腺五肽治疗复治菌阳肺结核的效果[J].国际流行病学传染病学杂志,2020,47(2):107-110.[20]赵兴忠,赵新国,朱峰.康复新液联合胸腺五肽治疗肺结核患者的效果及对免疫功能的影响[J].徐州医科大学学报,2020,40(7):505-508.[21]魏书青,高金昙,陈庆,等.康复新液辅助抗结核药治疗肠结核的疗效及对血清、肠黏膜血管内皮生长因子和核因子κB的影响[J].中国医院用药评价与分析,2022,22(2):165-168.

相似文献/References:

[1]谢 磊,李 芳,翟亚男.外用重组人碱性成纤维细胞生长因子联合康复新液治疗 糜烂型扁平苔藓的临床应用[J].医学信息,2018,31(18):124.[doi:10.3969/j.issn.1006-1959.2018.18.039]
　XIE Lei,LI Fang,ZHAI Ya-nan.Clinical Application of Recombiant Human Basic Fibroblast Growth Factor for External Use Combined with Kangfuxin Solution in the Treatment of Erosive Lichen Planus[J].Journal of Medical Information,2018,31(17):124.[doi:10.3969/j.issn.1006-1959.2018.18.039]
[2]邓云华.手术联合康复新液治疗肛周脓肿的疗效[J].医学信息,2019,32(22):150.[doi:10.3969/j.issn.1006-1959.2019.21.051]
　DENG Yun-hua.Therapeutic Effect of Combined Surgery and Rehabilitation Fluid on Perianal Abscess[J].Journal of Medical Information,2019,32(17):150.[doi:10.3969/j.issn.1006-1959.2019.21.051]

更新日期/Last Update: 1900-01-01